Mostafa Akbariqomi1, Reza Heidari1, Soraya Saleh Gargari2, Mir Davood Omrani3, Garshasb Rigi4,5, Nafiseh Sadat Sanikhani1, Hamid Kooshki6, Fatemeh Mahmoudian1, Mohammad Ali Mazlomi7, Gholamreza Tavoosidana8. 1. Department of Molecular Medicine, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran. 2. Department of Gynecology & Obstetric, Shohada Tajrish Educational Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran. 3. Department of Medical Genetics, Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran. 4. Department of Genetics, Faculty of Basic Science, Shahrekord University, Shahrekord, Iran. 5. Research Institute of Biotechnology, Shahrekord University, Shahrekord, Iran. 6. Nanobiotechnology Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran. 7. Department of Medical Biotechnology, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran. 8. Department of Molecular Medicine, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran. g-tavoosi@tums.ac.ir.
Abstract
PURPOSE: Methylated cell-free fetal DNA (cffDNA) in maternal plasma can potentially be used as a biomarker for accurate noninvasive prenatal testing (NIPT) of fetal disorders. Recovery and purification of cffDNA are key steps for downstream applications. In this study, we aimed to developed and evaluated different aspects of an optimized method and compared its efficiency with common methods used for extraction of methylated cffDNA. METHODS: Single factor experiments, Plackett-Burman (PB) design, and response surface methodology (RSM) were conducted for conventional Triton/Heat/Phenol (cTHP) method optimization. The total cell-free DNA (cfDNA) was extracted from pooled maternal plasma using the optimized method called the Triton/Heat/Phenol/Glycogen (THPG), cTHP method, a column-based kit, and a magnetic bead-based kit. In the next step, methylated cfDNA from the extracted total cfDNA was enriched using a methylated DNA immunoprecipitation (MeDIP) kit. Real-time quantitative polymerase chain reaction was performed on the RASSF1 gene and hyper region to determine the genomic equivalents per milliliter (GEq/ml) values of the methylated cfDNA and cffDNA, respectively. RESULTS: The optimum values of the significant factors affecting cfDNA extraction from 200 μl of plasma were 3% SDS, 1% Triton X-100, 0.9 μg/μl glycogen, and 0.3 M sodium acetate. The GEq/ml values of methylated cffDNA extracted using the THPG method were significantly higher than for the tested extraction methods (p < 0.001). CONCLUSIONS: Our results indicate that the THPG method is more efficient than the other tested methods for extraction of low copy number methylated cffDNA from a small volume of maternal plasma.
PURPOSE: Methylated cell-free fetal DNA (cffDNA) in maternal plasma can potentially be used as a biomarker for accurate noninvasive prenatal testing (NIPT) of fetal disorders. Recovery and purification of cffDNA are key steps for downstream applications. In this study, we aimed to developed and evaluated different aspects of an optimized method and compared its efficiency with common methods used for extraction of methylated cffDNA. METHODS: Single factor experiments, Plackett-Burman (PB) design, and response surface methodology (RSM) were conducted for conventional Triton/Heat/Phenol (cTHP) method optimization. The total cell-free DNA (cfDNA) was extracted from pooled maternal plasma using the optimized method called the Triton/Heat/Phenol/Glycogen (THPG), cTHP method, a column-based kit, and a magnetic bead-based kit. In the next step, methylated cfDNA from the extracted total cfDNA was enriched using a methylated DNA immunoprecipitation (MeDIP) kit. Real-time quantitative polymerase chain reaction was performed on the RASSF1 gene and hyper region to determine the genomic equivalents per milliliter (GEq/ml) values of the methylated cfDNA and cffDNA, respectively. RESULTS: The optimum values of the significant factors affecting cfDNA extraction from 200 μl of plasma were 3% SDS, 1% Triton X-100, 0.9 μg/μl glycogen, and 0.3 M sodium acetate. The GEq/ml values of methylated cffDNA extracted using the THPG method were significantly higher than for the tested extraction methods (p < 0.001). CONCLUSIONS: Our results indicate that the THPG method is more efficient than the other tested methods for extraction of low copy number methylated cffDNA from a small volume of maternal plasma.
Authors: K C Allen Chan; Jun Zhang; Angela B Y Hui; Nathalie Wong; Tze K Lau; Tse N Leung; Kwok-Wai Lo; Dolly W S Huang; Y M Dennis Lo Journal: Clin Chem Date: 2004-01 Impact factor: 8.327
Authors: Elisavet A Papageorgiou; Heike Fiegler; Vardhman Rakyan; Stephan Beck; Maj Hulten; Klea Lamnissou; Nigel P Carter; Philippos C Patsalis Journal: Am J Pathol Date: 2009-04-06 Impact factor: 4.307
Authors: Ji Hyae Lim; So Yeon Park; Shin Young Kim; Do Jin Kim; Ji Eun Choi; Min Hyoung Kim; Jun Seek Choi; Moon Young Kim; Jae Hyug Yang; Hyun Mee Ryu Journal: FASEB J Date: 2011-09-30 Impact factor: 5.191
Authors: H Christina Fan; Yair J Blumenfeld; Usha Chitkara; Louanne Hudgins; Stephen R Quake Journal: Proc Natl Acad Sci U S A Date: 2008-10-06 Impact factor: 11.205
Authors: Tobias J Legler; Zhong Liu; Ariadni Mavrou; Kirstin Finning; Ilona Hromadnikova; Silvia Galbiati; Cathy Meaney; Maj A Hultén; Francesco Crea; Martin L Olsson; Deborah G Maddocks; Dorothy Huang; Sylvia Armstrong Fisher; Markus Sprenger-Haussels; Aicha Ait Soussan; C Ellen van der Schoot Journal: Prenat Diagn Date: 2007-09 Impact factor: 3.050
Authors: Carolina J Jorgez; Dianne D Dang; Joe Leigh Simpson; Dorothy E Lewis; Farideh Z Bischoff Journal: Genet Med Date: 2006-10 Impact factor: 8.822